Top Industry Leaders in the Folliculitis Market
Valeant Pharmaceuticals Launched Eliquis (apixaban) with an extended indication for the prevention of venous thromboembolism (VTE) in patients undergoing surgery for hip or knee replacement, potentially reducing folliculitis risk associated with anticoagulant therapy.
Galderma Announced positive Phase 3 data for its investigational topical antibiotic, BPX-121, for the treatment of gram-negative folliculitis, offering a potential new option for this challenging type of folliculitis.
La Roche-Posay Introduced a new line of skincare products specifically formulated for sensitive skin prone to folliculitis, addressing the need for gentle and effective solutions.
Stelara Pharma Received FDA approval for its new topical corticosteroid ointment, Clobexasol Propionate 0.05%, for the treatment of inflammatory skin conditions like eczema, potentially offering relief for folliculitis associated with these conditions.
List of Folliculitis Key Companies in the Market
- AbbVie Inc. (US)
- Allergan (Republic of Ireland)
- AstraZeneca (UK)
- CELGENE CORPORATION (US)
- GlaxoSmithKline plc. (UK)
- Johnson & Johnson Services Inc. (US)
- Merck & Co. Inc. (US)
- Pfizer Inc.(US)
